Ultragenyx Data De-Risk Phase III Trial Of Setrusumab

 
• By Joseph Haas
  
Bone health
Ultragenyx's 14-month data for setrusumab shows sustained reduction of fractures • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D